InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (January 2024)
23 slides from InMed Pharmaceuticals's investor presentation, January 2024
Slide 1: Corporate Presentation
Corporate Presentation January 2024 :INM www.inmedpharma.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: anticipated development activities, timelines
Slide 3: Overview & Investment Highlights
Overview & Investment Highlights • Robust R&D pipeline with 4 candidates in dermatology, ocular and Alzheimer’s • Differentiated approach to the treatment of Alzheimer's • A successful Phase 2 dermatology program currently seeking partnerships • Extensive library of proprietary analogs for targeting
Slide 4: A Rare Cannabinoid Company
A Rare Cannabinoid Company RARE CANNABINOID EXPERTISE ACROSS SEVERAL AREAS Drug Discovery Pharmaceutical R&D Manufacturing Commercial • Pipeline of • Screening of therapeutic • Chemical and • B2B supplier to health pharmaceutical programs candidates biosynthesis expertise and wellness industry • Ski
Slide 5: Bringing Together a Depth of Cannabinoid Expertise
Bringing Together a Depth of Cannabinoid Expertise EXTENSIVE EXPERIENCE IN PHARMA R&D, CANNABINOID/API MANUFACTURING, CLINICAL AND REGULATORY Eric A. Adams, MIBS Michael Woudenberg, PEng Alexandra Mancini, MSc Eric Hsu, PhD Colin Clancy Chief Executive Officer Chief Operating Officer SVP, Clinical &
Slide 6: Cannabinoid Drug Development Programs
Cannabinoid Drug Development Programs
Slide 7: Pharmaceutical Development of Rare Cannabinoids
Pharmaceutical Development of Rare Cannabinoids HIGHLIGHTS SCREENING PRECLINICAL PH 1 PH 2 PH 3 NATURALLY-OCCURRING CANNABINOIDS • Phase 2 - Study completed INM-755 CBN • Showed a positive indication of enhanced anti-itch activity versus control cream Seeking Strategic Partnerships Epidermolysis bul
Slide 8: Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream
Phase 2 Clinical Trial: INM-755 Cannabinol (CBN) Cream Purpose of Trial Patient Enrollment Evaluate the safety of INM-755 CBN cream and obtain preliminary evidence of efficacy in treating symptoms and • Trial enrolled 19 patients wound healing in patients with EB. • 18 patients’ data were considered
Slide 9: Phase 2 Results: INM-755 Cannabinol (CBN) Cream
Phase 2 Results: INM-755 Cannabinol (CBN) Cream Key Results: Non-Wound Itch: Data breakdown Of the 18 participants assessed, chronic itch improved by a • A positive indication of enhanced anti-itch activity clinically meaningful amount in 12 patients (66.7%), of whom: for INM-755 cream versus the co
Slide 10: Glaucoma – A Leading Cause of Blindness for Age 60+
Glaucoma – A Leading Cause of Blindness for Age 60+ Unmet medical need Glaucoma market Current treatments do not proactively protect the eye or reverse the progression of glaucoma and only slow the progression of Second leading cause of blindness glaucoma by lowering intraocular pressure (IOP). worl
Slide 11: Age-related Macular Degeneration
Age-related Macular Degeneration CBN ANALOG DEMONSTRATED PROMISING EFFECTS RELATED TO THE TREATMENT OF AMD Unmet medical need AMD causes damage to the retina at the back of eye. Currently, AMD market there are no approved treatments for people with dry age-related macular degeneration, which account
Slide 12: INM-089: Increases Thickness of Retina in Preclinical AMD Model
INM-089: Increases Thickness of Retina in Preclinical AMD Model CANNABINOL ANALOG IMPROVES RETINAL FUNCTION INM-089 Preclinical Retina AMD Study Why cannabinoids for ocular disease? • Preserved retinal function in an in vivo Damaged Scientific research is pointing AMD disease model macula at the to
Slide 13: Alzheimer's Disease – Unmet Medical Need is High
Alzheimer’s Disease – Unmet Medical Need is High CANNABINOIDS MAY OFFER A NEW MULTIPRONGED APPROACH Unmet medical need Medications to treat Alzheimer’s target individual disease components Milestones and may slow the rate of cognitive decline but none have been shown to reverse its effects associate
Slide 14: INM-901 demonstrates promising effects in validated in vivo Alzheimer's disease models
INM-901 demonstrates promising effects in validated in vivo Alzheimer’s disease models POTENTIAL TO TARGET SEVERAL BIOLOGICAL PATHWAYS ASSOCIATED WITH ALZHEIMER’S DISEASE ALZ Behavioral Neuroprotection Neuritogenesis Studies Studies Studies • Basal and locomotor activity • Cytotoxicity model • Neuri
Slide 15: A Diverse Patent Portfolio
A Diverse Patent Portfolio 13 PATENT FAMILIES – NCEs/Formulations, Manufacturing Methods, Methods of Use NCEs Manufacturing Methods of use 2 patent families filed 7 patent families filed 4 patent families filed • 21 international pending • 2 granted • 2 granted • 29 international pending • 22 intern
Slide 16: BayMedica Commercial Business
BayMedica Commercial Business
Slide 17: BayMedica - Wholesale Rare Cannabinoids for the H&W Market
BayMedica -Wholesale Rare Cannabinoids for the H&W Market HIGH PURITY, CONSISTENT & BIOIDENTICAL TO NATURE CBC CBDV THCV CBT Cannabichromene Cannabidivarin Tetrahydrocannabivarin Cannabicitran CONSISTENCY C O S T- E F F E C T I V E N E S S High quality, bioidentical rare cannabinoids with exceptiona
Slide 18: BayMedica – Revenue Trending Positively
BayMedica – Revenue Trending Positively INCREASED DEMAND FOR BAYMEDICA’S BIOIDENTICAL RARE CANNABINOIDS 12 Month Trailing Sales US$ (000’s) Fiscal 2023 Revenue Growth US$ (000’s) $2.3M 2,500 +123% 5,000 4,500 2,000 4,000 3,500 1,500 3,000 $1.03M $895K 2,500 +120% -61% 1,000 $470K 2,000 1,500 $320K +
Slide 19: Corporate
Corporate
Slide 20: Financial Snapshot As of 2024-01-12
Financial Snapshot As of 2024-01-12 Cash and Short-term Investments $11.4 M(1) Shares I/O 9.6 M(2) Options 0.1 M Warrants and Preferred Investment Options (9.6M @$0.83 cents) 10.2 M Fully Diluted Shares 19.9 M Close US$0.38 52-week High US$2.33 52-week Low US$0.29 Avg. Daily Volume (Trailing 50 Days
Slide 21: Seasoned Board of Directors
Seasoned Board of Directors Andy Hull Janet Grove, QC Bryan Baldasare, Nicole Lemerond, CFA Eric A. Adams, MIBS Chair of Board of Directors Chair, Governance and Chair, Audit Committee Chair, Compensation Chief Executive Officer Nominations Committee Committee Andy Hull has over 30 years of Mr. Adam
Slide 22: Fiscal 2024 – Key Value Drivers
Fiscal 2024 – Key Value Drivers • Advance INM-901 in long-term preclinical in vivo studies and CMC preparation • Advance ocular program towards IND filing / human clinical trials in 2025 • Evaluate commercial partnerships for INM-755 • Target proprietary cannabinoid analogs for pharma R&D pipeline •
Slide 23: Thank you!
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES Thank you! Colin Clancy Vice President, Investor Relations & Corporate Communications [email protected] +1-604-416-0999 :INM www.inmedpharma.com
InMed Pharmaceuticals — Investor Presentation (January 2024) on 6ix